A prova sorológica de referência na leptospirose ainda é a soroaglutinação microscópica (SAM). Devido à complexidade desta prova avaliamos alguns testes rápidos para triagem dos anticorpos anti-leptospiras na fase aguda da infecção. Na década de 80, uma hemaglutinação passiva, utilizando frações polissacarídicas de leptospiras, foi considerada apropriada ao diagnóstico precoce, porém esta preparação antigênica incluía muitos “antígenos comuns” reconhecidos por anticorpos de 4% dos indivíduos normais. Um novo ELISA (enzyme-linked immunosorbent assay) utilizando uma suspensão de antígenos imunodominantes, resistentes à proteinase K, foi padronizado e avaliado quanto ao seu valor diagnóstico. Com 89,9% de sensibilidade e 97,4% de especificidade, esta técnica, referida como PK-ELISA, satisfaz os requisitos necessários para as provas de triagem da leptospirose humana. No entanto, em virtude de alguns reagentes usados nesta preparação antigênica serem importados e muito instáveis, foi proposta a introdução de novos métodos empregando-se anticorpos monoclonais. Em um “Acordo de Pesquisa Cooperativa” entre o Instituto Adolfo Lutz e o Laboratório Fleury foram produzidos hibridomas contra leptospiras. Dois deles foram selecionados para dar continuidade ao estudo: um, secretando anticorpos monoclonais (AcM) para um epítopo detectado em 16 de 23 sorovares do gênero Leptospira mais freqüentes em nosso meio (clone A12P4), e outro específico a somente um sorogrupo patogênico, icterohaemorragiae (clone H7P1). O AcM A12P4, uma imunoglobulina G2B (IgG2B), reagiu com epítopo presente nos componentes de pesos moleculares (PM) de 16-18 kDa dos lisados de leptospiras das cepas RGA e M-20, quando separados na eletroforese em gel de poliacrilamida, e com componentes de PM de 75-84kDa dos sorovares copenhageni e canicola. Por sua vez, o AcM H7P1, uma imunoglobulina G, reagiu com um epítopo comum a várias frações de PM acima de 21 kDa da cepa RGA e com componentes de PM de 21-22 kDa e de 75-82 kDa da cepa M-20. Os monoclonais foram empregados em provas imunoenzimáticas para a detecção de anticorpos específicos em amostras séricas pareadas coletadas de 52 pacientes com leptospirose, e do grupo controle que incluiu amostras séricas de 57 pacientes com outras doenças consideradas no diagnóstico diferencial, e de 68 indivíduos normais. Estas provas, no entanto, não foram satisfatórias. Finalmente, um novo ELISA foi desenvolvido no presente estudo que utiliza a suspensão de antígenos “AgMc”, purificados por cromatografia de afinidade utilizando a Sepharose 4B ativada com CNBr acoplada aos anticorpos monoclonais descritos acima. Os resultados obtidos com esta prova foram comparados aos obtidos com outros testes disponíveis em nosso meio, como a SAM e o ELISA clássico (ELISA c). Este novo método, o “ELISA AgMc”, com 80,70 % e 83,33 % de sensibilidade e especifidade, respectivamente, em relação à SAM; valores preditivos positivo e negativo de 69,70% e 90,10% respectivamente e índice de concordância geral de 82,49%, não parece ser um protocolo promissor para o diagnóstico rápido na leptospirose humana. Além disso, tomando-se a SAM como diagnóstico verdadeiro, os resultados obtidos no novo teste, após a conclusão diagnóstica do grupo de pacientes com a leptospirose, mostrou uma discordância significativa. São discutidas as possíveis explicações para os resultados encontrados. / The best serological test for leptospirosis laboratory diagnosis remains the microscopic agglutination test (MAT). Because of the complexity of MAT, we have been developed some rapid screening tests for leptospiral antibodies detection in the acute phase of infection. In the decade of 80, a passive hemagglutination test employing polysaccharide fractions of leptospires was considered appropriate for early diagnosis, but its antigen preparation included “common antigens” recognized by antibodies from 4% of healthy individuals. A new ELISA (enzyme-linked immunosorbent assay) employing proteinase K resistant immunodominant antigens was developed and its potential diagnosis evaluated. This technique, the PK-ELISA, presented 89.9% sensitivity and 97.4% specificity, and satisfied the requeriments needed for serological screening tests of human leptospirosis. However, some of the reagents used in its antigen preparation are imported and very unstable. So, it was proposed, in a “Cooperative Research Accordance” between Instituto Adolfo Lutz and Laboratório Fleury, to try new approaches with monoclonal antibodies. Two hibridomas secreting specific monoclonal antibodies (MAb) were selected: one, against an epitope detected in 16 of 23 members of the genus Leptospira (clone A12P4) and the other, specific to the icterohaemorragiae serogroup (clone H7P1). The MAb A12P4, a G2 (IgG2B) immunoglobulin, reacted with an epitope present in the 16-18 kDa components of icterohaemorragiae serogroup and with the 75-84 kDa components of serovars copenhageni and canicola, after whole-cell lysates of the leptospires were separated by sodium dodecyl sulfate- polyacrylamide gel electrophoresis. The MAb H7P1, which is an IgG, reacted with an epitope common to several fractions of molecular weight above 21 kDa of strain RGA and with the 21-22 kDa and the 75-82 kDa components of strain M-20. Both monoclonal antibodies were employed in enzyme immunoassays for detecting specific antibodies in serum samples serially colleted from 52 patients with leptospirosis, and from the control group, which consisted of sera from 57 patients with other diseases included in the differential diagnosis, and from 68 healthy individuals. These tests, however, were not satisfactory. A new ELISA was developed in the present study employing an antigen suspension “AgMc”, purified by affinity chromatography with CNBr-activated Sepharose 4B coupled to the monoclonal antibodies described above. The results obtained with this test were compared to the MAT and to the classical IgM ELISA (ELISA c). The new method, “AgMc ELISA”, presented serological indices, relatively to reference test MAT, of 80.70 % and 83.33 % of sensitivity and specificity, respectively; positive and negative predictive values of 69.70 % and 90.10 %, respectively, and general agreement index of 82.49 %. So, this test was not considered a promising approach to rapid diagnosis of human leptospirosis. Moreover, the proportion of patients diagnosed as having leptospirosis by the “AgMc ELISA” and the MAT differ significantly. The possible explanations for the results obtained are discussed.

Made available in DSpace on 2014-08-20T13:32:53Z (GMT). No. of bitstreams: 1 dissertacao_leonardo_monte.pdf: 1685536 bytes, checksum: 2128191ebf9a0b395668fcbb7af16da9 (MD5) Previous issue date: 2009-05-11 / Leptospirosis is a zoonotic disease caused by pathogenic bacteria belonging to the Leptospira genus. Several mammals may carry the agent, and rats are the most important source of human infection in urban settings. The wide spectrum of clinical manifestations varies from mild cases, with fever and headaches, to severe presentations, with liver and kidney failure, which may lead to death. As a result of the various degrees of severity, leptospirosis is frequently mistaken, in its acute stage, with other tropical diseases such as influenza and dengue. The microscopic agglutination test (MAT) is considered the gold standard when diagnosing leptospirosis; however, the test presents limitations regarding sensitivity in the acute phase of the disease. Recently, surface proteins LigA and LigB have been identified to be related with leptospiral virulence. These proteins have been characterized as adhesins, with a proteic structure similar to Escherichia coli intimin and Yersinia pseudotuberculosis invasin, which are important virulence factors in these organisms. The goal of this study was to produce and characterize monoclonal antibodies (MAbs) against a truncated fragment of approximately 54 kDa, named rLigBrep, that comprise a identical portion of LigA and LigB (domains 2-7). The 5 MAbs obtained were of the IgG1 (2) and IgG2b (3) isotypes and their affinity constants for rLigBrep varied from 7 x 107 M-1 to 4 x 108 M-1. The MAbs were able to react with the native antigen in L. interrogans serovar Copenhageni strain Fiocruz L1-130 by indirect immunofluorescence, immunoblotting, whole-cell ELISA and immunoelectron microscopy. These results allow concluding that these MAbs are important tools for studies aiming understanding the role of Lig proteins in Leptospira pathogenesis and in the development of tests for diagnosis of leptospirosis. / A leptospirose é uma zoonose causada por bactérias patogênicas pertencentes ao gênero Leptospira. Diversos mamíferos podem albergar o agente, sendo o rato a principal fonte de infecção para humanos no ambiente. As manifestações clínicas da doença variam desde os sintomas leves, como febre e dores de cabeça, até os mais graves com insuficiência renal e hepática que podem levar o indivíduo à morte. Esse amplo espectro de sintomas faz com que a leptospirose seja freqüentemente confundida em sua fase aguda com outras doenças febris, como gripe e dengue. O teste de aglutinação microscópica (MAT) é considerado o padrão ouro para o diagnóstico laboratorial da leptospirose, entretanto, o teste apresenta limitações relacionadas com a sensibilidade na fase aguda da doença. Recentemente, as proteínas de superfície LigA e LigB foram identificadas e relacionadas com a virulência de leptospiras patogênicas. Estas proteínas foram caracterizadas como adesinas, possuindo estrutura protéica semelhante a intimina de Escherichia coli e invasina de Yersinia pseudotuberculosis, que são importantes fatores de virulência nestes microrganismos. O objetivo desse estudo foi produzir e caracterizar anticorpos monoclonais (MAbs) contra um fragmento truncado de aproximadamente 54 kDa, que codifica a região idêntica das proteínas LigA e LigB (domínios 2-7), denominado rLigBrep. Foram obtidos 5 MAbs dos isotipos IgG1 (2) e IgG2b (3), com afinidades por rLigBrep que variaram entre 7 x 107 M-1 e 4 x 108 M-1. Foi comprovado através de imunofluorescência indireta, immunoblotting, ELISA whole-cell e microscopia imunoeletrônica que os MAbs foram capazes de detectar o antígeno nativo presente em L. interrogans sorovar Copenhageni cepa Fiocruz L1-130. Estes resultados permitem concluir que os MAbs produzidos são importantes ferramentas para serem utilizados em estudos que visam entender o papel das proteínas Lig na patogênese das leptospiras e em testes diagnósticos para leptospirose.

Un nouveau couple de récepteurs de co-signalisation (BTLA/HVEM) a récemment été proposé comme un acteur important dans l’échappement tumoral. L'expression d’HVEM a été identifiée dans la plupart des cancers. Son niveau expression est inversement corrélé avec la survie des patients. L'expression d’HVEM par des cellules tumorales pourrait inhiber la réponse immunitaire à travers BTLA exprimé par les lymphocytes T.Ainsi, dans notre travail, des anticorps monoclonaux (mAb) ciblant HVEM ont été évalués dans un modèle de souris NSG greffées avec des lymphocytes T et des tumeurs humaines. Nous avons tout d’abord caractérisé un clone anti-HVEM avec une forte affinité in vitro. Le clone choisi pour notre étude a montré sa capacité à favoriser l’activation des lymphocytes T humains in vivo, attesté par une aggravation des symptômes et de la mortalité associée au transfert de PBMC humains chez la souris. L’effet anti tumoral observé en l’absence de transfert adoptif était renforcé en présence de lymphocytes T, suggérant un effet additif de l’anticorps sur la tumeur et les lymphocytes T. Une diminution des lymphocytes T régulateurs et une augmentation de la prolifération des lymphocytes T CD8+ dans la tumeur était parfois associée à ce retard de croissance.En reproduisant un environnement partiellement humain chez la souris NSG, nous avons pu évaluer l'effet thérapeutique d’un mAb anti-HVEM dans le développement de deux types de tumeurs humaines et son impact sur le système immunitaire humain. Nos résultats indiquent qu’HVEM, de par son expression par la tumeur et les lymphocytes T, pourrait être une piste judicieuse pour l’immunothérapie du cancer. / A new pair of co-signaling receptors (BTLA / HVEM) has recently been proposed as an important actor in tumor escapement. HVEM expression has been identified in wild type of cancers. Its expression level is inversely correlated with patient survival. Expression of HVEM by tumor cells could inhibit the immune response through BTLA expressed by T lymphocytes.Thus, in our work, monoclonal antibodies (mAb) targeting HVEM were evaluated in a model of NSG mice grafted with human T cells and tumors. We first characterized an anti-HVEM clone with high affinity in vitro. The clone selected for our study showed its ability to promote activation of human T lymphocytes in vivo as evidenced by worsening symptoms and mortality associated with human PBMC transfer in mice. The anti-tumor effect observed in the absence of adoptive transfer was enhanced in the presence of T lymphocytes, suggesting an additive effect of the antibody on the tumor and T lymphocytes. A decrease in regulatory T lymphocytes and an increase in the proliferation of CD8 + T lymphocytes in the tumor was sometimes associated with this growth retardation.By reproducing a partially human environment in NSG mice, we were able to evaluate the therapeutic effect of an anti-HVEM mAb in the development of two types of human tumors and its impact on the human immune system. Our results indicate that HVEM, by its expression by the tumor and the T lymphocytes, could be a judicious track for the immunotherapy of the cancer.

Les anticorps monoclonaux anti-tumoraux sont produits en cellules eucaryotes. Pour des raisons de temps et de cout, peu de candidats sont sélectionnés après des tests in vitro pour être produits à large échelle et testés in vivo. Pour tester plus d’anticorps plus rapidement, nous souhaitons produire des fragments variables simple chaine (scFv) chez E. coli. et les coupler à un fragment constant Fc par chimie click pour reconstituer des mimes d’immunoglobulines naturelles. Cette production indépendante des fragments est aussi un outil modulaire permettant de combiner rapidement un grand nombre scFv et de Fc différents.La chimie click est basée sur une réaction spécifique et de haut rendement entre un azide et un cyclooctyne. Les fragments ont donc été fonctionnalisés sur des résidus spécifiques (tags) par des composés chimiques pour introduire ces fonctions à leur extrémité. La première étape a consisté à introduire des tags en C-terminal du scFv anti-HER2 4D5 et en N-terminal du Fc d’IgG1 humaine. Les scFv ont été produits en cytoplasme d’E. coli à hauteur d’au moins 100 mg/L puis oxydés in vitro au sulfate de cuivre. Le fragment Fc a été produit classiquement en cellules humaines. Cinq réactions chimiques ou enzymatiques ont été optimisées et comparées en termes de spécificité et de rendement. La conjugaison d’une amine sur un tag glutamine catalysée par la transglutaminase microbienne a donné les meilleurs résultats. Le scFv a ainsi été dérivé par l’azadibenzocyclooctyne et le Fc par l’azide à hauteur de 60-70%. Lorsqu’ils sont mélangés, ces fragments forment un (scFv)2-Fc et un scFv-Fc avec des rendements globals respectifs de 10-20% et 20-30% après optimisation.Les mélanges scFv + Fc après réaction de chimie click se fixent de la même façon que le (scFv)2-Fc eucaryote au récepteur HER2. Il reste désormais à montrer que leur capacité à inhiber la prolifération d’une lignée exprimant ce récepteur est similaire. L’objectif final est d’obtenir une inhibition de croissance tumorale similaire sur des xénogreffes. / Anti-tumoral monoclonal antibodies are currently produced in eukaryotic cells. For cost and time reasons, a limited number of potential candidates are selected after in vitro tests. They are produced at large scale and then tested in vivo. To test more antibodies and more rapidly, we chose to produce single chain variable fragments (scFv) in bacteria, and to couple them to the eukaryotic constant fragment (Fc) thanks to click chemistry to reconstitute immunoglobulin-like compounds. For a given cost, this enables to produce and test in vivo a larger number of clones. This independent production of fragments is also a flexible tool allowing the combination of different Fc isotypes/allotypes with different scFvs.Click chemistry is based on a specific and high-yield reaction between and azide and a cyclooctyne. Therefore, antibody fragments were functionalised on specific residues (tags) by chemical linker so that each part will contain one of these chemical moieties at their extremity. The first step consisted in introducing tags into the anti-HER2 scFv 4D5 C-terminus and human IgG1 Fc N-termini sequences. The scFvs were produced with yields higher than 100 mg/L in the E. coli cytoplasm and in vitro oxidized with copper sulfate. The Fc fragment was classically produced in human cells. Five chemical or enzymatical reactions were optimised and compared in terms of specificity and yield. The coupling between an amine and a glutamine tag catalysed by microbial transglutaminase gave the best results. The scFv fragment was thus functionalised with an azadibenzocyclooctyne and the Fc fragment with an azide at 60-70%. When mixed together, these fragments formed a (scFv)2-Fc and a scFv-Fc with global yields respectively of 10-20% and 20-30% after optimisation.After the click reaction, the scFv + Fc mix binds to the HER2 receptor on the same way as the eukaryotic (scFv)2-Fc in terms of HER2-binding and proliferation inhibition capacity. Now, it must be demonstrated that their proliferation inhibition of a HER2-positive cell line is similar. The final aim is to get a similar tumour growth inhibition on murine xenografts.

A sperm specific and species conserved monoclonal antibody (HS-63) was shown to inhibit in vitro fertilization of mouse oocytes and human sperm penetration to zona-free hamster ova. The sperm antigen (SA-63) which reacts with HS-63 was found to be localized on the sperm acrosome. Following sperm capacitation, this antigen becomes exposed and is shed after the acrosome reaction. SA-63 may be involved in the sperm acrosome reaction during the initial fertilization process. Sperm antigen (SA-63) from mouse (MSA-63) was purified from mouse testes with soluble and detergent extraction procedures followed by immunoaffinity chromatography. The purified MSA-63 antigen was shown to be a group of proteins with a size ranging from 25 Kd to 50 Kd and pIs of about 4.2 when analyzed by two dimensional gel electrophoresis. MSA-63 antigen may be associated with actins in its native form. A proteolytic activity was found in the solution of purified MSA-63 preparation. Purified MSA-63 was used for immunization of mice and rabbits. Following successive immunizations, antisera of high titres were raised and reacted specifically with sperm acre-some. The isoimmune sera from immunized mice exhibited significant inhibition on in vitro fertilization of mouse oocytes. Complementary deoxyribonucleic acid (cDNA) fragments encoding the MSA-63 were cloned from a mouse testis cDNA library by using an immunoscreening method with rabbit antisera against MSA-63 as the detecting probe. When a specific cDNA probe was used for Northern blot analysis, an mRNA of 1.5 Kb in size was detected only in the adult mouse testis, but not in any other somatic tissues. By Southern blot analysis, it was also demonstrated that the gene encoding for SA-63 protein is conserved among different mammalian species. The location of SA-63 antigen gene was determined to be on human chromosome 11 when analyzed with a blot of a human-hamster somatic cell hybrid panel. By DNA sequence analysis, a protein of 28 Kd in size was deduced from the MSA-63 cDNA. The amino acid sequences of trypsin-digested peptide fragments of MSA-63 were used to verify that deduced amino acid sequence from the cDNA. The recombinant fusion proteins containing MSA-63 protein fragment were produced in E. coli and used to immunize female mice. Similar to the original HS-63 monoclonal antibody, the antisera thus produced reacted only with the sperm acrosome and revealed significant inhibition of the in vitro fertilization of mouse oocytes. In the developing mouse testis, the expression of MSA-63 gene was found to be post-meiotic. Protein and mRNA of MSA-63 were not produced until day 20 after birth. / Medicine, Faculty of / Obstetrics and Gynaecology, Department of / Graduate

1 CHARLES UNIVERSITY FAKULTY OF PHARMACY IN HRADEC KRÁLOVÉ DEPARTMENT OF BIOPHYSICS AND PHYSICAL CHEMISTRY DISSERTATION THESIS RADIOLABELED ANTIBODIES - THE PERSPECTIVE FOR DIAGNOSIS AND THERAPY Supervizor: Mgr. PAVEL BÁRTA, Ph.D. HRADEC KRÁLOVÉ, 2017 Bc. JANA MEJTSKÁ 2 ABSTRACT EN Different types of tissues have a characteristic cell morphology. Each cell has typical molecules on its surface, which may be either of physiological or pathological type. The presence of these surface structures can be interesting for possible modulation of specific cell populations from neighboring cells. Utilization of this property is then essential particularly in a case of tumor cells. Targeting on tumor specific cell structures involves the use of receptor specific peptides or monoclonal antibodies. The discovery of the preparation of monoclonal antibodies has opened a new chapter in the treatment and diagnosis not only tumor diseases. The advantage of monoclonal antibodies is their specificity and also high affinity to the type of the target cell structures. This study is focused on the summary of monoclonal antibodies which are currently being applied on the treatment or diagnosis of a particular cancer. Furthermore, this work also includes antibodies which are under development for intended medical applications with...

No description available.

As células dendríticas (DCs) expressam receptores que reconhecem padrões moleculares associados a patógenos (PAMPs), sendo capazes de capturar, processar e apresentar antígenos para os linfócitos. O contato com PAMPs induz a maturação das DCs e, consequentemente, a ativação dos linfócitos. Nossa estratégia para desenvolver vacinas é empregar anticorpos monoclonais contra os receptores endocíticos DEC205 e DCIR2, presentes nas subpopulações de DCs, em fusão com o antígeno de interesse. E estimular a maturação delas utilizando os adjuvantes poly I:C, CpG ODN 1826 e flagelina de S. Typhimurium . Imunizamos camundongos selvagens ou knockouts para os receptores TLR 3, 5 e 9 com adjuvantes e anticorpos quiméricos anti-DEC205, anti-DCIR2 ou isotipo controle (Iso) fundidos a proteína MSP119 de Plasmodium vivax. Avaliamos as repostas humoral e celular no grupos imunizados. Os resultados indicam que, seja qual for o adjuvante usado, a maioria dos parâmetros analisados aponta para a superioridade do direcionamento do antígeno para o receptor DEC205. / Dendritic cells (DCs) express receptors that recognize pathogen-associated molecular patterns (PAMPs), and are able to capture, process and present antigens to lymphocytes. In recent years, a immunization strategy that directs antigens to DCs in vivo has been developing. This consists in the use of monoclonal antibodies fused with the antigen of interest. However, effective immune activation occurs mainly when the chimeric antibodies anti-DEC or anti-DCIR2 are administered in the presence of a DC maturation stimulus. We immunized wild type and knockout mice for TLR3, 5 and 9 with adjuvants (poly I:C, CpG ODN 1826 and flagellin from S. typhimurium) and chimeric anti-DEC205, anti-DCIR2 or isotype control fused to the Plasmodium vivax MSP119 protein. After the administration of two doses, we evaluated the humoral and cellular immune responses in the different groups. Our results indicate that, irrespectively of the adjuvant, the majority of parameters analyzed points out to the superiority of antigen targeting to the DEC205 receptor.

Imunidade protetora depende da geração e manutenção do repertório de linfócitos T de memória. A geração dessas células está correlacionada com a apresentação de antígenos pelas células dendríticas (DCs). O direcionamento de antígenos tem sido estudado como um novo método vacinal que consiste em entregar antígenos diretamente para DCs usando anticorpos monoclonais. O principal objetivo desse trabalho foi direcionar uma proteína de Plasmodium para a subpopulação DEC205+ de DCs. Camundongos foram imunizados e então desafiados dias depois, com esporozoítos de P. yoelii. A proteína direcionada não protegeu camundongos do desafio, mas a proteína não direcionada protegeu, alcançando níveis de proteção estéril em torno de 100% em alguns casos. Observamos correlação entre a quantidade dos anticorpos e a proteção relativa dos animais imunizados com a proteína não direcionada. Além disso, utilizando anticorpos monoclonais demonstramos que a região conhecida como major repeat pode ser utilizada como alvo direto de pesquisas em vacinas contra malária. / In general, protective immunity against many pathogens depends on the generation of memory T cells, and the survival of cells for a long period of time after initial contact with pathogens. We know that the generation of these cells is correlated with the activation of parasite-specific immune cells and the presentation of antigens for dendritic cell (DCs). Targeting antigens to DCs has been studied as a new vaccination method, delivering antigens directly to DCs using monoclonal antibodies. The goal was target circunsporozoite protein (CSP), from Plasmodium, to a DEC205+ (DC) subset. Mice were immunized and challenged days later using P. yoelii sporozoites. Targeting protein did not protect mice from challenge, but non-targeting CS lead to 100% of protection. We found correlation between levels of antibody with protection, and high levels of anti-CS IgG in mice immunized with non-targeting protein. Using monoclonal antibodies we were able to map major repeat as a potential target for new researches in malaria vaccine.

Angiogênese é a formação de novos vasos sanguíneos a partir de vasos já existentes e é importante em processos fisiológicos, que em adultos é restrita ao reparo tecidual e ao ciclo reprodutivo feminino. Entretanto, doenças, como câncer ou retinopatias, induzem a formação da angiogênese patológica, necessária para a progressão destas patologias. Anticorpos monoclonais constituem uma das classes de biofármacos que mais cresce e com impacto importante nas doenças dependentes de angiogênese. Entre as diversas metodologias para a identificação de anticorpos monoclonais contra alvos terapêuticos, está o phage display. Por causa do fator de crescimento endotelial vascular (VEGF) ser o principal fator responsável pela formação de novos vasos, o principal biofármaco anti-angiogênico disponível na clínica atualmente é um anticorpo monoclonal (bevacizumab) direcionadas contra o VEGF. Embora terapias anti-VEGF sejam eficazes, ainda não são ideais devido a efeitos colaterais indesejados e a resistência medicamentosa. Novas alternativas são necessárias a fim de aperfeiçoar as terapias angiogênicas. O objetivo do nosso estudo é identificar novos alvos moleculares e desenvolver novos agentes terapêuticos para doenças dependentes de angiogênese. Para atingirmos nossa meta escolhemos o sistema de phage display para selecionarmos anticorpos com propriedades angiogênicas. Uma biblioteca de de anticorpos foi desenvolvida em nosso laboratório, dirigida contra a molécula VEGF, em particular uma de suas isoformas. Os animais imunizados desenvolveram anticorpos específicos, detectados por ELISA e Western-blot. A amplificação do pool de genes das cadeias leve e pesada de imunoglobulinas foi realizada para produzir os fragmentos single-chain (ScFv) que foram então clonados no vetor para a construção da biblioteca. A biblioteca de display de anticorpos ScFv será, portanto, analisada em plataformas angiogênicas para isolar anticorpos específicos contra isoformas de VEGF e novos marcadores moleculares de superfície celular expressos por células endoteliais ativadas. / Angiogenesis is the formation of new blood vessels from pre-existing ones and is an important physiological process, which in adults is mostly restricted to wound healing or the female reproductive cycle. However, different illnesses, such as cancer or retinopathies, induce the formation of pathological angiogenesis, necessary for disease progression. Monoclonal antibodies are one of the fastest growing class of biopharmaceuticals with important implications in angiogenesis dependent diseases. Among various methods for the identification of monoclonal antibodies against therapeutic targets is phage display technology. Because the vascular endothelial growth factor (VEGF) is the main molecular factor responsible for the formation of new blood vessels, the major anti-angiogenic drug available in the clinic today is a monoclonal antibody (bevacizumab) directed against VEGF. However, although anti-VEGF therapies are effective, they are not yet ideal due to undesirable side effects and drug resistance. Novel alternatives are necessary to improve on angiogenic therapies. The aim of our study is to identify novel molecular targets and to develop new therapeutic agents for angiogenic dependent diseases. To achieve our goal we have chosen the phage display system in order to select for antibodies with angiogenic properties. An antibody phage library has been developed in our laboratory, directed against VEGF molecule, particularly one of it isoforms. The animals were immunized and developed specific antibodies, detected by ELISA and Western-blot. Amplification of the pool of light and heavy chain Ig genes was performed to produce the single chain (ScFv) fragments for library construction. The ScFv antibody display libraries will be then screened in angiogenic settings to isolate antibodies against specific VEGF isoforms and novel cell surface molecular markers expressed by activated human endothelial cells